Posters
« Back
Tumor microenvironment analysis provides insights into the activity of CD8 T-cells and their impact on survival
EP27289
Poster Title: Tumor microenvironment analysis provides insights into the activity of CD8 T-cells and their impact on survival
Submitted on 17 Feb 2018
Author(s): Ashwini Patil, MS1, Nitin Mandloi, MS1, Kiran V. Paul, MS1, Malini Manoharan, PhD1, Priyanka Shah, PhD1 , Sushri Priyadharshini , MS1, Rohit Gupta, PhD1, and Amitabha Chaudhuri, PhD1, Ravi Gupta, PhD1
Affiliations: MedGenome Inc, Foster City, California
This poster was presented at Frontiers in Cancer Immunotherapy
Poster Views: 632
View poster »


Poster Information
Abstract: CD8+ T cells are present at varying levels in different cancers. For example, 35% of melanoma have high CD8+ T cell infiltration compared to 1% of prostate cancer. This is one reason why checkpoint inhibitors work well in melanoma, but has poor efficacy in prostate cancer. The human immune system detects and kills tumors by mobilizing cytotoxic T lymphocytes (CTLs). However, a combination of factors derived from the tumor cells and the tumor microenvironment regulate the ability of CD8+ T cells to effectively destroy tumor cells. Summary: Tumor microenvironment analysis provides insights into the activity of CD8 T-cells and their impact on survival
References: Ledford, H., T-cell therapy extends cancer survival to years. Nature, 2014. 516(7530): p. 156. - https://www.ncbi.nlm.nih.gov/pubmed/25503214
2. Ledford, H., Cancer treatment: The killer within. Nature, 2014. 508(7494): p. 24-6. - https://www.ncbi.nlm.nih.gov/pubmed/24695297
3. Kyi, C. and M.A. Postow, Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett, 2014. 588(2): p. 368-76. - https://www.ncbi.nlm.nih.gov/pubmed/24161671
4. Callahan, M.K., M.A. Postow, and J.D. Wolchok, CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol, 2014. 4: p. 385. - https://www.ncbi.nlm.nih.gov/pubmed/25642417
5. Wolchok, J.D., et al., Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med, 2017. 377(14): p. 1345-1356. - https://www.ncbi.nlm.nih.gov/pubmed/28889792
6. Luksza, M., et al., A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017. 551(7681): p. 517-520. - ht
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons